• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
    • Corporate Videos
  • Development Programs
    • Biopharmaceutical Trials
    • Group Strategy and Target Markets
    • NTI164
    • Clinical Trials
    • Pathways to Commercialisation
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Investor Conference Calls  
    • Company Reports
    • Presentations
    • News & Media
    • Fact Sheets
    • Analyst Reports
    • Right to Receive Documents
  • Contact

News &
Media

  • Stockhead: Neurotech partners with University of Sydney to advance Rett syndrome program

    18 February 2026
    View More: Stockhead: Neurotech partners with University of Sydney to advance Rett syndrome program
  • Stockhead: Neurotech gets crucial ethics approval to start phase III autism trial

    2 February 2026
    View More: Stockhead: Neurotech gets crucial ethics approval to start phase III autism trial
  • Stockhead: Peer-reviewed PANS data strengthens the case for Neurotech’s NTI164

    28 January 2026
    View More: Stockhead: Peer-reviewed PANS data strengthens the case for Neurotech’s NTI164
  • Stockhead: Neurotech hopes to ride the medical cannabis deregulation Trump Bump

    21 January 2026
    View More: Stockhead: Neurotech hopes to ride the medical cannabis deregulation Trump Bump
  • Stockhead: Neurotech raising $4 million to drive NTI164 development

    17 December 2025
    View More: Stockhead: Neurotech raising $4 million to drive NTI164 development
  • Who’s Who with NTI: Neurotech Ieads the way in paediatric neurology treatments

    21 October 2025

    Read the full article here

    View More: Who’s Who with NTI: Neurotech Ieads the way in paediatric neurology treatments
  • Neurotech Secures Rare Pediatric Disease Designation for NTI164 in Rett Syndrome

    8 October 2025

    Read the full article here

    View More: Neurotech Secures Rare Pediatric Disease Designation for NTI164 in Rett Syndrome
  • Neurotech scores US FDA rare disease win for NTI164 in Rett syndrome

    8 October 2025

    Read the full article here

    View More: Neurotech scores US FDA rare disease win for NTI164 in Rett syndrome
  • Long Shortz with Neurotech: Dual strategy positions NTI164 for autism and Rett markets

    7 October 2025

    Read the full article here

    View More: Long Shortz with Neurotech: Dual strategy positions NTI164 for autism and Rett markets
Previous
1 2 3 4 … 11
Next

Footer

Suite 102 / Level 1, 55 Collins Street
Melbourne VIC 3000
Australia

moc.l1794157634anoit1794157634anret1794157634nihce1794157634torue1794157634n@ofn1794157634i1794157634

+61 (3) 9498 3132

Subscribe to our latest announcements

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2026 Neurotech International • Site by White Noise Communications

Download prospectus